126 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
.
Operating Expenses
GAAP
% Change
Non-GAAP(a)
% Change
($ in millions)
Q1 2024
Q1 2023
Q1 2024
Q1 2023
Research and development (R&D)
Acquired … .
** Percentage not meaningful
GAAP and non-GAAP R&D expenses increased in the first quarter of 2024, compared to the first quarter of 2023, driven
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
diversified our revenue base and made important progress in our robust R&D pipeline," said Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President … of Regeneron. "In 2024, we plan to continue investing heavily in internal R&D, driving commercial execution with targeted promotion, and prudently deploying
8-K
EX-99.1
ifzdzk037k0rl2mc9ou
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
SC TO-T
EX-99
53ztkuk
25 Aug 23
Third party tender offer statement
7:46am
8-K
EX-99.1
8uo2om7hafajger23cgw
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
8-K
EX-99.1
tazeuy5dyyt33eshqs
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am
8-K
EX-99.1
f2r2hs4 1xe7
3 Nov 22
Regeneron Reports Third Quarter 2022 Financial and Operating Results
7:19am
8-K
EX-99.1
w1dl 5lqf8
3 Aug 22
Regeneron Reports Second Quarter 2022 Financial and Operating Results
7:08am